

**Consensus or Controversy? Investigators Discuss Clinical Practice Patterns and Available Research Data Guiding the Management of Multiple Myeloma****THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.**

- 1. Which of the following progression-free survival outcomes was reported in the ENDURANCE trial evaluating carfilzomib, lenalidomide and dexamethasone (KRd) versus bortezomib, lenalidomide and dexamethasone (RVd) as initial therapy for patients with newly diagnosed multiple myeloma (MM)?**
  - a. KRd was superior to RVd
  - b. KRd was not superior to RVd**
- 2. What was observed in the randomized Phase II GRIFFIN trial evaluating the addition of daratumumab to RVd for patients with newly diagnosed MM who were eligible for autologous stem cell transplant?**
  - a. Higher rates of stringent complete response (sCR) and minimal residual disease (MRD)-negative status with daratumumab/RVd**
  - b. Higher rates of sCR and MRD-negative status with RVd alone
  - c. No difference in the rates of sCR and MRD-negative status between the study arms
- 3. Which of the following strategies is effective in preventing or mitigating the side effects associated with selinexor in the treatment of MM?**
  - a. Antiemetic medication**
  - b. Steroid mouthwash
  - c. Both a and b
  - d. None of the above
- 4. What is the target of the various CAR (chimeric antigen receptor) T-cell platforms under evaluation for patients with MM?**
  - a. CD19
  - b. BCMA (B-cell maturation antigen)**
  - c. CD20
- 5. Which of the following drug types best describes the novel agent melflufen?**
  - a. Antibody-drug conjugate
  - b. CELMoD (cereblon E3 ligase modulator)
  - c. Peptide-drug conjugate**